Page 23 - தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List

[December 28, 2020] Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL) (2020 Edition) for the treatment of melanoma by the China National Healthcare Security Administration (NHSA). The primary drug format specification is the 80mg(2ml)/vial. Toripalimab is the only anti-PD-1 monoclonal antibody for the treatment of melanoma that has been included in the NRDL. Melanoma is an aggressive form of solid tumor with a rapid systemic dissemination. Toripalimab received a conditional approval by the NMPA for the 2

United statesSan franciscoJunshi biosciencesEli lillyJun guoInstitute of microbiology chinese academy scienceIr teamRenal cancer expert committeeChina national healthcare security administrationNational reimbursement drug listNational healthcare security administrationPr teamChina national reimbursement drug listChinese society of clinical oncologyBiosciences announces inclusionChina national reimbursement drug

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China s National Reimbursement Drug List

[December 28, 2020] Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China s National Reimbursement Drug List SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULAÂ® has been included in the updated National Reimbursement Drug List (NRDL) released by Chinaâs National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Dburns mcclellanMike zanoniBilly choWilliam liangRyo imai robert flammZai labZai lab limitedZai lab annual report on formChina national healthcare security administrationExchange commissionNational reimbursement drug listZai lab announces inclusionChina national reimbursement drug listZai lab forwardLab announces inclusionNational reimbursement drug

Zai Lab Announces Inclusion of ZEJULA (Niraparib) in China s National Reimbursement Drug List Seite 1

29.12.2020 - SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement . Seite 1

William liangNational reimbursement drug listZai labZai lab limitedChina national healthcare security administrationLab limitedNational healthcare security administrationChief executive officerChief commercialவில்லியம் லியாங்தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல்ஜா ஆய்வகம்ஜா ஆய்வகம் வரையறுக்கப்பட்டவைஆய்வகம் வரையறுக்கப்பட்டவைதலைமை நிர்வாகி அதிகாரிதலைமை வணிகரீதியானது

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Hong kongKeith grossmanChristopher peetzWilliam liangNovo nordiskZai labVirios therapeuticsGilead sciences incAprea therapeutics incLiquidia corpZai lab licensed ovarian cancer drug eligibleZai lab ltdAlkermes plcBristol myers squibb coInhibikase therapeutics incEuropean medicines agency for ozempic

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) - Press Release

®, including anaphylaxis that has been reported with use of XGEVA ®. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue XGEVA ® therapy permanently. Patients receiving XGEVA ® (denosumab). Osteonecrosis of the jaw (ONJ) has been reported in patients receiving XGEVA ®, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ. In clinical trials in patients with cancer, the incidence of ONJ was higher with longer duration of exposure.

United statesHong kongNew zealandUnited kingdomUnited arab emiratesSaudi arabiaMacau generalBristol myers squibbXiaobin wuYork heart association classBeigene ltdChina national healthcare security administrationExchange commissionChina national medical products administrationNational reimbursement drug listEuropean union